SCHEMBL3015412

SCHEMBL3015412

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 3/20 0.49
MAPT P10636 2/20 0.49
HSD17B10 Q99714 2/20 0.49
RECQL P46063 1/20 0.49
NPSR1 Q6W5P4 3/20 0.46
KDM4E B2RXH2 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 2/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
GFER P55789 1/20 0.46
PKM P14618 2/20 0.43
TSHR P16473 3/20 0.43
LMNA P02545 3/20 0.43
MAPK1 P28482 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007925 0.93 MEN1 (0.46) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3005294 0.92 TP53 (0.56) KMT2AUSP2MAPTHSD17B10RECQL
SCHEMBL3013485 0.92 MAPT (0.58) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3006243 0.92 MEN1 (0.52) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3006909 0.92 HSD17B10 (0.47) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3022582 0.91 ALDH1A1 (0.48) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3003954 0.91 MAPT (0.49) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3015005 0.91 MAPT (0.46) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3012360 0.90 HSD11B1 (0.48) MEN1KMT2AUSP2MAPTHSD17B10
SCHEMBL3005487 0.90 USP2 (0.47) MEN1KMT2AUSP2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.